|
|
| Maladies Infectieuses > Etude de marché sectorielle |
|
|
|
|
€ 3 160,00 |
Editeur
: |
Global Industry Analyst |
Langue
: |
Anglais |
Date de publication : |
Juin 2007 |
Taille du document : |
914 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 48 pages | Mars 1999 | Anglais
|
|
|
| Main
focus: |
vaccines,vaccine,hepatitis b,immunology,...,...
|
| Research
focus: |
market outlook,demand analysis,industry structure, |
| Geographic
focus: |
usa,france,united kingdom,canada,switzerland,japan,... |
| |
|
|
|
|
| 118 pages | Décembre 2002 | Anglais
|
|
|
| Main
focus: |
health care,vaccines,vaccine,hepatitis b,...
|
| Research
focus: |
industry structure,market definition, |
| Geographic
focus: |
india,usa,switzerland,france,united kingdom,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Antivirals Market Outlook: Market analysis of future growth and leading players by sector
178 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an |
2 443,75 €
|
| |
| |
Approved AIDS and AIDS-Related Drugs, 1987-2003
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pipeline Insight: Hepatitis B - New Kids on the Block
211 pages | Avril 2005 |
IntroductionAccording to the WHO, 350-400 million people are chronically infected with HBV progresses to liver cirrhosis and hepatocellular carcinoma.
Previously HBV has been treated with lamivudin |
9 120,00 €
|
| |
| |
04-013: Overview of Autoimmune Disease Research
162 pages | Juin 2004 |
This overview will help life science suppliers identify opportunities to expand the placement of their immunological tools and technologies as well as assist in stimulating new product ideas and/or en |
800,00 €
|
| |
| |
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Recommendations for Diagnostic Testing for Hepatitis B
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Commercial Perspectives: HIV - Benchmarking Rapid Antiretroviral Uptake
181 pages | Février 2005 |
IntroductionHistorically, HIV antiretrovirals have differed markedly in their speed of market uptake.
Now, to win market share in an already mature market, newly launched products need not only a s |
9 120,00 €
|
| |
| |
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
329 pages | Décembre 2004 |
IntroductionAccording to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV.
Although HBV vaccination and routine screening of donated blood has decreased inciden |
12 160,00 €
|
| |
| |
Chinese Markets for Vaccine
269 pages | Mars 2003 |
China's demand for vaccine has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trends, |
2 835,00 €
|
| |
| |
Monoclonal Antibody Therapies: Evolving into a $30 billion market
360 pages | Avril 2005 |
IntroductionThe monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004.
It has the p |
12 160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The major product segments analyzed are Prophylactic Vaccines (Pediatric Prophylactic Vaccines, & Adult Prophylactic Vaccines), and Therapeutic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual forecasts are provided for each region for the period of 2001 through 2010. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 164 companies including many key and niche players worldwide such as ALK – Abelló, Acambis, Bavarian Nordic, Crucell N.V., CSL Ltd., GlaxoSmithKline, GlaxoSmithKline Biologicals, Medimmune, Inc, Merck & Company, Inc., Novartis Vaccines, Sanofi-Aventis, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics, Vaxin, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
|
|
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II.Executive Summary
1. Market Overview & Outlook II-1
2. Product Overview II-6
3. Market Trends & Issues II-53
4. Distribution Channels II-63
5. Technological Developments II-64
6. Clinical Trials II-69
7. Research Breakthroughs II-83
8. Product Development II-85
9. Product Developments In Recent Past II-87
10. Product Launches II-89
11. Recent Industry Activity II-92
12. Focus on Select Global Players II-154
13. Global Market Perspective II-161
III. MARKET
1. The United States III-1
2. Canada III-68
3. Japan III-72
4. Europe III-75
4a. France III-82
4b. Germany III-89
4c. The United Kingdom III-93
4d. Italy III-105
4e. Spain III-108
4f. Russia III-110
4g. Rest of Europe III-113
5. Asia-Pacific III-126
6. Latin America III-147
7. Rest of World III-151
IV. COMPETITION
1. Abiogen Pharma SpA (Italy) IV-1
2. Acambis PLC (UK) IV-2
3. ACE BioSciences (Denmark) IV-6
4. ADImmune Corporation (Taiwan) IV-7
5. Advaxis Inc. (USA) IV-8
6. Adventrx Pharmaceuticals, Inc. (USA) IV-10
7. Akzo Nobel NV (The Netherlands) IV-13
8. ALK - Abello (Denmark) IV-26
9. Alphavax Human Vaccines, Inc. (USA) IV-29
10. American Biogenetic Sciences, Inc. (USA) IV-30
11. Amgen, Inc. (USA) IV-31
12. AnGes MG, Inc. (Japan) IV-37
13. Antigenics, Inc. (USA) IV-40
14. Argos Therapeutics BV (The Netherlands) IV-44
15. Avant Immunotherapeutics, Inc. (USA) IV-45
16. Avantogen Ltd. (USA) IV-49
17. Avax Technologies, Inc. (USA) IV-51
18. Bavarian Nordic (Denmark) IV-53
19. Baxter International, Inc. (USA) IV-56
20. Bharat Biotech International Ltd. (India) IV-70
21. Bio-Bridge Science, Inc. (USA) IV-71
22. Biocon India (India) IV-72
23. BioDiem Ltd. (Australia) IV-78
24. Biogen Idec, Inc. (USA) IV-79
25. Bioject Medical Technologies, Inc. (USA) IV-87
26. Biological E Ltd. (India) IV-92
27. Bio-Manguinhos (Brazil) IV-95
28. Biomira, Inc. (Canada) IV-96
29. Biosante Pharmaceuticals, Inc. (USA) IV-99
30. Biotech Consortium India Ltd. (India) IV-102
31. Biovex Ltd. (UK) IV-103
32. Biovirx, Inc. (USA) IV-103
33. Bristol-Myers Squibb Company (USA) IV-104
34. Cadila Pharmaceuticals Limited (India) IV-114
35. Cancer Therapeutics, Inc. (USA) IV-117
36. Cell Genesys, Inc. (USA) IV-119
37. Celldex, Inc. (USA) IV-125
38. Cel-Sci Corporation (USA) IV-126
39. Center D’immunologie Pierre Fabre (France) IV-129
40. Cerus Corporation (USA) IV-130
41. China Biopharma, Inc. (USA) IV-133
42. Chongqing Jiachen Bio-Engineering Limited (China) IV-134
43. Cobra Biomanufacturing PLC (UK) IV-135
44. Coley Pharmaceutical Group, Inc. (USA) IV-138
45. Crucell NV (The Netherlands) IV-141
46. CSL Ltd. (Australia) IV-147
47. CT International (USA) IV-155
48. CytoDyn, Inc. (USA) IV-157
49. Cytogen Corporation (USA) IV-158
50. Cytomatrix LLC (USA) IV-162
51. CytRx Corporation (USA) IV-163
52. Dendreon Corporation (USA) IV-165
53. Denka Seiken Co., Ltd. (Japan) IV-167
54. DNAVEC Corporation (Japan) IV-173
55. DOR Biopharma, Inc. (USA) IV-174
56. Duphar VV (The Netherlands) IV-176
57. Dynavax Technologies Corporation (USA) IV-177
58. DynPort Vaccine Company LLC (USA) IV-181
59. Eisai Co., Ltd. (Japan) IV-183
60. Emergent BioSolutions, Inc. (USA) IV-191
61. F. Hoffmann-La Roche Ltd. / Roche Holding Ltd.
62. Fiocruz / Fundacao Oswaldo Cruz Fiocruz (Brazil) IV-206
63. Gene Medicine Japan, Inc. (Japan) IV-206
64. Genencor International, Inc. (USA) IV-207
65. Genphar, Inc. (USA) IV-214
66. GenVec, Inc. (USA) IV-216
67. GeoVax Labs, Inc. (USA) IV-222
68. Geron Corporation (USA) IV-224
69. GlaxoSmithKline PLC (UK) IV-228
70. Haffkine Biopharmaceutical Corporation Ltd. (India) IV-251
71. Hawaii Biotech, Inc. (USA) IV-252
72. Henogen SA (Belgium) IV-253
73. Hepalife Technologies, Inc. (USA) IV-254
74. Hindustan Antibiotics Ltd. (India) IV-255
75. Hindustan Latex Ltd. (India) IV-257
76. Human Genome Sciences, Inc. (USA) IV-260
77. Idera Pharmaceuticals, Inc. (USA) IV-269
78. IDM Pharma, Inc. (USA) IV-271
79. ImClone Systems, Inc. (USA) IV-274
80. Immunoscience, Inc. (USA) IV-276
81. Imuna Pharm AS (Slovakia) IV-277
82. Indian Immunologicals Ltd. (India) IV-279
83. Inhibitex, Inc. (USA) IV-282
84. Innogenetics NV (Belgium) IV-284
85. Inovio Biomedical Corporation (USA) IV-288
86. Intas Pharmaceuticals Ltd. (India) IV-294
87. Intercell AG (Austria) IV-295
88. Interferon Sciences, Inc. (USA) IV-297
89. InterMune, Inc. (USA) IV-298
90. International Vaccine Institute (Korea) IV-302
91. Introgen Therapeutics, Inc. (USA) IV-304
92. Juvaris BioTherapeutics, Inc. (USA) IV-308
93. Kaketsuken (Japan) IV-309
94. King Pharmaceuticals, Inc. (USA) IV-310
95. Kogen Limited (UK) IV-316
96. Laboratorios Leti SA (Spain) IV-317
97. LG Life Sciences (Korea) IV-318
98. Ligocyte Pharmaceuticals, Inc. (USA) IV-319
99. Maxygen, Inc. (USA) IV-320
100. MediGene AG (Germany) IV-323
101. MedImmune, Inc. (USA) IV-326
102. Medusa Biotechnology Corporation Sdn. Bhd. (Malaysia) IV-333
103. Merck KGaA (Germany) IV-334
104. Micromet, Inc. (USA) IV-354
105. MUbio Products BV (The Netherlands) IV-357
106. Nabi Biopharmaceuticals (USA) IV-358
107. Nederlands Vaccin Instituut (The Netherlands) IV-363
108. Nordic Vaccine A/S (Denmark) IV-364
109. Northwest Biotherapeutics, Inc. (USA) IV-365
110. Novartis AG (Switzerland) IV-367
111. Novavax, Inc. (USA) IV-388
112. NovoVacs BV (The Netherlands) IV-393
113. NPO Petrovaks Pharm (Russia) IV-393
114. Omnia Biologics, Inc. (USA) IV-394
115. Oxxon Therapeutics Ltd. (UK) IV-396
116. Panacea Biotec Limited (India) IV-398
117. Panacos Pharmaceuticals, Inc. (USA) IV-402
118. Pepscan Systems (The Netherlands) IV-405
119. Pevion Biotech Ltd. (Switzerland) IV-408
120. Pfizer, Inc. (USA) IV-409
121. Pharmexa A/S (Denmark) IV-421
122. Philogen Srl (Italy) IV-424
123. Prima Biomed Limited (Australia) IV-425
124. Progenics Pharmaceuticals, Inc. (USA) IV-426
125. Protherics Plc (UK) IV-430
126. PT. Bio Farma (Indonesia) IV-433
127. Ranbaxy Laboratories Ltd. (India) IV-434
128. Sachsisches Serumwerk GmbH (Germany) IV-446
129. Sanofi-Aventis (France) IV-447
130. Scigen Ltd. (Australia) IV-459
131. Serum Institute of India (India) IV-462
132. Shanta Biotechnics Limited (India) IV-464
133. Shenzhen Neptunus Interlong Bio-Technique Co., Ltd. (China) IV-466
134. Singvax Pte Ltd. (Singapore) IV-467
135. Sinovac Biotech Ltd. (China) IV-468
136. Solvay SA (Belgium) IV-470
137. South African Vaccine Producers (Pty), Ltd. (South Africa) IV-482
138. Stallergenes (France) IV-483
139. Synergy Vaccines, Inc. (USA) IV-484
140. Takeda Chemical Industries Ltd. (Japan) IV-485
141. Targeted Genetics Corporation (USA) IV-494
142. Teva Pharmaceutical Industries Ltd. (Israel) IV-498
143. The Immune Response Corporation (USA) IV-510
144. Therion Biologics Corporation (USA) IV-515
145. Torlak Institute of Immunology & Virology (Serbia/Montenegro) IV-516
146. Transgene SA (France) IV-518
147. USV Limited (India) IV-520
148. Vaccinoma, Inc. (Australia) IV-521
149. Valentis, Inc. (USA) IV-522
150. VaxGen, Inc. (USA) IV-526
151. Vaxin, Inc. (USA) IV-528
152. Vical, Inc. (USA) IV-529
153. Virax Holdings Limited (Australia) IV-532
154. Virexx Medical Corporation (Canada) IV-533
155. Virionics Corporation (USA) IV-534
156. Viropro, Inc. (Canada) IV-535
157. Vivalis (France) IV-537
158. Wave Biotech LLC (USA) IV-538
159. Wockhardt (India) IV-540
160. Wyeth (USA) IV-546
161. Wyoming DNA Vaccine LLC (USA) IV-555
162. Xenova Group PLC (UK) IV-556
163. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China) IV-559
164. Zydus Cadila Healthcare Ltd. (India) IV-560
|
|
|
PPLSEN
|
|
|
|
|
